Back to search

Aristotle University Of Thessaloniki (AUTH)

Ανάπτυξη και πιλοτική δοκιμή βοηθήματος λήψης αποφάσεων για ασθενείς με σακχαρώδη διαβήτη τύπου 2: μελέτη μεικτών μεθόδων σε πολλαπλά στάδια

Abstract

dc:description

Aim: Development and pilot testing of a decision aid tool for patients with type 2 diabetes mellitus. Methods: A multi-stage mixed methods study was conducted. The first stage included a survey study to determine which treatment outcomes and medication attributes are considered important by patients and clinicians for therapeutic decisions in type 2 diabetes. The second stage included a systematic review and network meta-analysis to assess the comparative efficacy and safety of antidiabetic drugs. The third stage included the development and pilot testing of a decision aid for T2DM. Results: Based on data from 6556 patients with T2DM and 363 clinicians in the survey study, patients were more likely than clinicians to rate prevention of diabetic eye disease, sexual dysfunction, amputation, and stroke as important. Clinicians were more likely than patients to rate reduction in HbA1c, body weight, all-cause mortality, and risk for hypoglycemia. Compared with clinicians, patients were less concerned about drug cost, but more concerned about route of administration and need for less frequent glucose self-monitoring. In the second stage, data from 453 studies assessing 21 antidiabetic interventions (320,474 patients with T2DM) given as monotherapies, add-on to metformin-based therapies (296 trials), or as monotherapies versus add-on to metformin therapies (23 trials) were included. No differences were evident between treatments in drug-naive patients at low cardiovascular risk. Treatment with specific GLP -1 receptor agonists and insulin regimens added to metformin-based background therapy was associated with greater reductions in HbA1c level. In patients at low cardiovascular risk receiving metformin-based background treatment (298 trials), no clinically meaningful differences between treatments for mortality and vascular outcomes were evident. In patients at increased cardiovascular risk receiving metformin-based background therapy (21 trials), treatment with oral semaglutide, empagliflozin, liraglutide, extended-release exenatide, and dapagliflozin reduced all-cause mortality. Oral semaglutide, empagliflozin, and liraglutide also reduced cardiovascular mortality, while subcutaneous semaglutide and dulaglitide reduced odds of stroke. Treatment with SGLT -2 inhibitors reduced hospitalization for heart failure and end-stage renal disease. Subcutaneous semaglutide increased odds of diabetic retinopathy, while canagliflozin increased odds of amputation. In the third stage, the developed decision aid reduced patients’ decisional conflict, and improved knowledge and patients’ and clinicians’ satisfaction. Conclusions: The development and pilot testing of decision aid for the treatment of T2DM was associated with improved decision-making process. Future evaluation in a randomized controlled trial will further elucidate its effectiveness in clinical practice.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2024

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Avgerinos, Ioannis
  • Αυγερινός, Ιωάννης

Subjects

dc:subject × 20

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/55964

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Avgerinos, Ioannis; Αυγερινός, Ιωάννης. Ανάπτυξη και πιλοτική δοκιμή βοηθήματος λήψης αποφάσεων για ασθενείς με σακχαρώδη διαβήτη τύπου 2: μελέτη μεικτών μεθόδων σε πολλαπλά στάδια. Aristotle University Of Thessaloniki (AUTH), 2024. http://hdl.handle.net/10442/hedi/55964